Member Info for Qd22

Thanks barchid.

PS. However Amati buying in earlier this year was a very good sign: they're very strong on Smaller Companies, plus they'll have the chance to interrogate them personally.

"The Group's year-to-date performance gives confidence that it will comfortably exceed its stated revenue guidance of not less than $83m for the full year 2021. While the Group expects to deliver revenue beyond its initial expectations, the need to increase staffing levels, onboard customers and manage certain other costs associated with capturing this additional opportunity may temper the profit impact of this revenue outperformance.
Whilst cost management remains a key priority, management remains focused on capturing the range of new opportunities ahead of it and driving profitable revenue growth over the long-term. This long-term opportunity is underpinned by the global trends driving increased ecommerce adoption in the Group's end-markets."

Don't know what to make of this. Tempted to be very cynical. Glad I bought a bundle at 189p, but still underwater. Can't understand how they have managed to miss the opportunities for them in social distancing with their virtual queuing - and are they now paying themselves a bonus for achieving nothing?? What are these "certain other costs associated with capturing this additional opportunity"?

Lost faith but loath to leave.

That's against 2020 revenue of £87.7m, up from 2019 of £64.1.

"Following successful manufacture of large-scale batches of AstraZeneca's COVID-19 Vaccine, AstraZeneca has today committed to an increase in the number of batches required from Oxford Biomedica in the second half of 2021. As a result of this, the Group is raising revenue guidance for expected cumulative revenues from AstraZeneca by the end of 2021 from in excess of £50 million to in excess of £100 million, and as a result expects significant growth in Group Operating EBITDA in the year ending 2021."

That'll do!

Woodstock, that's very worrying.

I'm in the vulnerable category, and have been using the mouthwashes after significant contact with people. It's no loss, reassuring, and just £1.99 in Home Bargains! Just make sure you shake it before use, otherwise you get a mouthful of oil, and I suspect lessen the effectiveness of the rest of the bottle. I think the oil makes it stay on your epidermis for a while and that's why it's so effective.

I would normally prefer mint, but tbh it makes me gag, and I much prefer the clove flavour.

Been recommending it to friends and family, but I suspect hardly anyone took me up on it. Strange that when lessening risk is so easy we find it so hard to do. However the average mainland Chinese (with whom I have a lot of contact) is much more thorough, and many need/use mouthwash anyway for other reasons. With the right marketing I could see it becoming a major player in the market there.

Just noticed that an Israeli fund 'Ark Israel Innovative Technology' raised its stake from 1.1m to 4.2m shares, reported end March. That's quite a jump, and while I've never heard of them, the fact that they are probably Israeli is interesting.

It's a frustrating long wait here. I really should learn to take profits when spikes begin to falter. I did last May at just under £1, but not later.

goldstandard you will have noticed that they do a gold standard saliva based PCR test, but it needs lab processing. Otherwise I don't know if this is sputum-based: "The Group's COVID-19 antigen test has 4+1 gene discovery capability, including the S protein, compared with a market standard of one to three gene discovery. This enables it to provide more accurate results, reducing the risk of false positives and false negatives. The Group is now offering its 4+1 kit as its standard COVID-19 antigen test, which is being delivered to several private and government customers in Europe and other geographies." That was 24/12/20, and since they don't mention it it probably isn't.... but no harm in banging the drum!

Don't say much because I'm not qualified. Yes, the 10 and 20 year charts are lovely.
Probably bought following your lead, Rivaldo [thanks!], in 2019, then topped up X2 last year, and am up nearly 50%. Thanks again!

FWIW I use Stockopedia, which loves it rating it 94/100, and especially high on Quality and Momentum - which seem to me to be the ones that count more than Value over the long term. RNWH is the kind of main economy stock I would listen to Stockopedia on. Institutional investment pretty stable at 53%, and it qualifies for 3 long screens, all momentum based. Broker consensus is high and rising. You will note I leave the important stuff - the figures - to others!

As an AIM stock it's possible it qualifies for IHT relief if you hold it for 2 years and pop off, and being in "highly regulated and secure sectors for many years to come", and seeming to be a nice quiet steady grower may be worth looking at. DYOR on that! It may not qualify anyway.

I would be interested to know, Rivaldo, what initially brought this company to your attention?

£3m EBIDTA. Repaying debt, and tax deferrals.... Sounds good to me.

"The objective to reduce net debt remains a priority for the Group and we have continued our rigorous focus on working capital efficiencies, cash conversation and cost management. This has enabled us to repay an additional £2.3 million of our term loan - over and above the scheduled quarterly payments. Our banking partner, HSBC, has waived the requirement of covenant measurements for the first half of the year ending March 2022.

Over the last 18 months, net debt has significantly reduced by £8.4 million; as of 30 September 2019, net debt was £11.1 million and at 31 March 2021 was £2.7 million, net of cash balances of £1.3 million. At 31 March 2021, Bilby had deferred £1.0 million VAT liabilities which post year-end, in agreement with HMRC, have started to be paid."

"Over the last 9 months, Microtox© PD units have achieved the ability to detect SARS-CoV-2 in wastewater.

..... In addition to SARS-CoV-2, Microtox© PD units have positively detected and identified E.coli bacteria in drinking water with 99.3% accuracy in 3.37 seconds. Current standard test results after sampling typically return in 2-5 days."

E. Coli is bacterial and so viral SARS-Cov-2 is a different ball game, but they are doing it and it is incredible. If they can achieve the same standard with SARS-Cov-2 then it's incredibly important. Clearly the investment is going in.

Well, I've just topped up at 128.08.

But I'm just so disappointed and saddened at the story of this last year. A year ago it was clear - before the phase II came out - that the company had a highly significant treatment. Only if the virus had something quite different would it not work. Well since then every trial has shown it DOES work. It works in the lungs, where it is designed to work! Hence that severe breathlessness is the key measure.

It is British. It has been in the public eye. Quite a few of us have written to our MPs about it. Every test and trial is positive. And 1 year on, and 3,183,177 deaths later [you can probably at least double that in reality], and we're still waiting for it to be deployed. NO urgency in government. Oh.....!

1. Severely breathless patients clearly benefit from the drug, and therefore are far less likely to become dangerously ill.

2. It can easily be administered at home.

Thus, to me, it's incredibly applicable to 3rd world, such as India at the moment.

My only question is how this would mix with dexamethasone, which may be applicable at the same stage of disease and be equally easy to dose at home.

Interesting. Money Week's cover story this week was Aviation, and they recommended that aircraft manufacturer based in Derby... "...sales....should grow by 17% this year. The group also has exciting products in the pipeline, including the UltraFan turbine, which is expected to boost fuel efficiency further - by up to 25% compared with earlier engines."

Thank you.

Hi Fantasy. Why did I think you were not a holder? I interpreted "Before anyone starts, no plans to buy, not touching vast with a barge pole" as you not being a holder. Looking at your other posts I do see that you hold, from a long time back. Well, I wish you good fortune. This could I suppose explode [either way], but yesterday I did something I have never done before: quickly sold what I had bought, at a loss. I hadn't done my research properly, didn't realise how dicey the management is. I have held companies to the bitter end before, with dubious management, for a story I believed in, and lost the lot. That's OK in a way, but it's simply a gamble, risk/reward that goes the wrong way. There's an element of that in every investment, and sometimes they go the right way. But do I need to do it with a BoD I have no confidence in? It makes it only about money, and I don't want to be like that. I don't want to be simply gambling, for the money. I invest in things I believe in, and I think that should include the management team as well. There's enough alternatives out there not to have to sit in what feels to me like a muddy pool. I realise some people won't think much of this, but all the best anyway! Best wishes to you all: I hope it does well.

In-long, stay away from my lawn!! Lol.

Otherwise, great post, thank you.

Fantasy thank you for all your time putting down your views, given that you are not a holder. Others too. You certainly know the history, and it's appreciated. At the moment this is exactly what I see a BB as being for: differing views, expressed with the reasoning, and without slanging. Usually the opposing views are few and far between, and tend to get shouted down. So thanks to all.

It's one to watch like a hawk...

Basically, if they're telling the truth the risk/reward looks worth it.

Turnover nearly doubled, EBIDTA up nearly 6 X. That'll do. Expecting a jump today, after the long fall back.